Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 27, 2019
Brainsway Reports Financial Results for Fourth Quarter and Full-Year 2018
HACKENSACK, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- Brainsway Ltd. (BRIN.TA), a leader in the advanced non-invasive treatment of brain disorders, has issued the Company’s ...
March 27, 2019
Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28
JERUSALEM, March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), announced today that it will report financial results for the fourth quarter and year ...
March 27, 2019
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
SYDNEY, Australia, March 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...
March 26, 2019
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of ...
March 26, 2019
Pfenex to Present at the 18th Annual Needham Healthcare Conference
SAN DIEGO, March 26, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex ...
March 26, 2019
CorMedix Confirms Previously Announced One-For-Five Reverse Stock Split
BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 25, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
March 26, 2019
BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
LUND, Sweden and STRASBOURG, France, March 26, 2019/PRNewswire/ -- BioInvent International AB (OMXS:BINV), a biotech company focused on the discovery and development of novel immuno-regulatory ...
March 26, 2019
InspireMD Announces 1-for-50 Reverse Stock Split
TEL AVIV, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus ...
March 26, 2019
iCAD to Present Corporate Overview at the Jefferies 2019 Radiation Oncology & Energy-Based Therapeutics Summit
NASHUA, N.H., March 26, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ...
March 26, 2019
Eiger BioPharmaceuticals to Participate in Conferences in April
PALO ALTO, Calif., March 26, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare ...
March 26, 2019
Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers
SALT LAKE CITY, March 26, 2019 /PRNewswire/ -- Lipocine Inc.(LPCN), a specialty pharmaceutical company, announced today acceptance of their abstract for late-breaker presentation on LPCN 1144 ...
March 26, 2019
Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope
NEW YORK, March 26, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that two oral and four poster presentations related to its Ac-225 ...
March 26, 2019
MediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018
YAVNE, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe ...
March 26, 2019
Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program
MOUNTAIN VIEW, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- Scilex Holdings, Inc. (“Scilex”), a majority owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), today ...
March 26, 2019
Prometic to Report its Fourth Quarter and 2018 Year-End Financial Results and Hold Conference Call / Webcast
LAVAL, QC , March 26, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it  will report its financial ...
March 21, 2019
Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results
VANCOUVER , March 21, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...
March 21, 2019
Chiasma Announces Three Poster Presentations at ENDO 2019
WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and ...
March 21, 2019
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, ...
March 21, 2019
Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in ...
March 21, 2019
BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
LUND, Sweden , March 21, 2019 /PRNewswire/ --BioInvent International AB (OMXS:BINV), focused on the discovery and development of novel and first-in-class immuno-regulatory antibody-based medicines generated by ...
Page 34 of 169